Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

acute gouty arthritis(1,2). Patients had suffered from three or more gouty arthritis attacks in the previous 12 months and were either unresponsive or intolerant to common therapies like NSAIDs or colchicine, or these treatments were contraindicated. Patients were randomized to receive a single dose of ACZ885 150 milligrams (mg) via subcutaneous (s.c.) injection or TA 40 mg via intramuscular (i.m.) injection(1,2). In the case of a new attack, patients received a new dose of the same treatment they were randomized to at baseline.

Both studies had the same two primary endpoints: pain intensity at 72 hours post-dose; and time to the first new gouty arthritis attack(1,2). Pain in the affected joint was measured according to an internationally recognized pain scale, the Visual Analog Scale (VAS).

In one study, patients treated with ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 73.3 mm at baseline to 28.1 mm for ACZ885 vs. 74.8 mm at baseline to 39.5 mm for TA (p=0.0005)(1,16). Similarly, patients in the other study receiving ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 74.9 mm at baseline to 22.1 mm for ACZ885 vs. 73.6 mm at baseline to 31.9 mm for TA (p=0.0018)(17).

The number of patients with new attacks across both studies was also significantly reduced with ACZ885 compared to TA(2). In the first study, nearly twice as many patients experienced a new gouty arthritis attack in the TA group compared to ACZ885 (40 vs. 21 patients respectively [p=0.0061])(18). In addition, in the second study nearly three times as many patients in the TA group experienced a new attack compared to ACZ885 (42 vs. 15 patients respectively [p=0.0001])(18). In the previous year, patients in both studies suffered an average of at least six attacks (6.5 for ACZ885 and seven for TA in study one; and 6.5 and 5.9 respectively in study two)(16,17).

ACZ885 was generally wel
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... - The issue: In consultation ... lot (lot 710535) of Clavulin-400 (70mL) after receiving a complaint ... in one bottle of the  product. No other lots of ... Clavulin-400 is an oral antibiotic used in adults and children ... Clavulin-400 comes as a powder in bottles and is mixed ...
(Date:4/17/2015)... N.C. , April 17, 2015 ... the Integrated Embolic Protection™ filter platform for angioplasty ... of a $5.6 million Series B financing round ... venture firm with a focus on medical devices, ... The round also included Mountain Group Partners, Lookout ...
(Date:4/17/2015)... , April 17, 2015  Regulatory leaders in the ... bipartisan discussion draft called "21 st Century Cures." ... to be taken up by Congress soon and if ... medical device products are developed and marketed in ... many companies have begun to consider how the proposed ...
Breaking Medicine Technology:Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle 2Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 321st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2
... able to save part of each kidney in ... tumors appear on preoperative,scans, MEMPHIS, Tenn., March ... demonstrated that children with bilateral,Wilms tumor, a cancer ... both,kidneys by undergoing a procedure called bilateral nephron-sparing ...
... Pre-existing Lamivudine Resistance Predisposes Patients to ... Higher Rates of BARACLUDE Resistance ... data presented today demonstrated a continued low incidence of,resistance ... nucleoside-naive chronic hepatitis B patients analyzed, no additional,patient developed ...
Cached Medicine Technology:St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
(Date:4/19/2015)... Houston, Texas (PRWEB) April 19, 2015 ... is pleased to announce the publication of white paper ... Online Affair . As online media provides a ... whole new niche market specifically targeting adulterous spouses ... which an affair becomes as easy as shopping online. ...
(Date:4/18/2015)... April 19, 2015 The Residential ... during the past five years. The industry, which provides ... unable to fully care for themselves, has boomed on ... for dementia care for seniors with memory impairment. As ... an annualized rate of 4.1% to $1.9 billion over ...
(Date:4/18/2015)... PA (PRWEB) April 18, 2015 "I ... evacuation stretchers in healthcare facilities," said an inventor from ... alternative storage system." , He developed the Slyde Door ... doors used in healthcare facilities. It provides convenient storage ... there are more stretchers available for patients. , ...
(Date:4/18/2015)... 2015 Lower-auto-insurance.com has released a new ... auto insurance quotes . , Drivers can find ... quotes. A professional insurance brokerage website can help drivers ... a simple, convenient way. The whole process is designed ... , Comparing online car insurance quotes is advantageous because ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released ... they say, “exposes a tactical shift by cyberattackers.” With everything ... introduced in 2014 - almost a million a day - ... be identified and patched by prominent manufacturers – as long ... business in a digital world can be fraught with peril, ...
Breaking Medicine News(10 mins):Health News:McCann Investigations Publishes White Paper Married, but Dating: The Rise of the Married Online Affair 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Residential Senior Care Franchises in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5
... prevention office of the Ministry of Health released a data ... which//, around 45,000 new cases of eyesight loss are reported ... reported 12 million people handicapped with eye problems, including about ... director with the blindness prevention office in East China's Shandong ...
... sickness or Human African trypanosomiasis is caused by the bite ... passes on the parasite called the trypanosome, to human beings ... disease over the past two decades in Sub-Saharan Africa. The ... of the number of people suffering this sickness, which is ...
... for protection of traditional medicines that they say is ... practitioners. ,Mei Zhinan, an expert in traditional ... said 80 percent of China's 55 minority groups, accounting ... billion population, had their own traditional medicines and secret ...
... accredited NewYork-Presbyterian Hospital as a Bariatric Surgery Center Network ... recognition of the Hospital's ability to offer patients the ... for New York state and one of only seven ... 20 years of age and older are obese -- ...
... by S. Kankova and colleagues from the Departments of ... Reproductive Medicine; and GynCentrum, in the Czech Republic, women ... than women who are Toxoplasma negative. // ... in human with a universal occurrence of 20-80%. This ...
... role in longevity, with longer-lived rodents showing significantly lower ... new study has found.// ,The study further strengthens ... shorter its life, and vice versa, said Mario Pinto, ... regulate metabolic rate. ,“Thyroid hormones are key ...
Cached Medicine News:Health News:Understanding Sleeping Sickness 2Health News:Understanding Sleeping Sickness 3Health News:Chinese Experts Call for Protection of Traditional Medicines 2Health News:NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery 2Health News:Effect of parasitic infection on baby's sex 2Health News:Longer-Lived Rodents Have Lower Levels of Thyroid Hormone 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: